MedTrace Logo

Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type

NCT00861120 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2012-10-26

No results posted yet for this study

Summary

The purpose of this study is to investigate the response rate in platinum-resistant, KRAS wild-type, ovarian cancer patients who are treated with pegylated liposomal doxorubicin (Caelyx®) in combination with biological treatment panitumumab (Vectibix®).

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Pegylated liposomal doxorubicin

40 mg/m2 on day 1 of a 28 days cycle

DRUG

Panitumumab

6 mg/kg on days 1 and 15 of a 28 days cycle

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, MD, DMSc · Vejle Hospital

  • Karina D. Steffensen, MD, PhD · Vejle Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • Austria
  • Belgium
  • Denmark
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00861120 on ClinicalTrials.gov